



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 9/42, 9/52, B01J 13/02 C07F 9/10	A1	(11) International Publication Number: WO 88/ 04924 (43) International Publication Date: 14 July 1988 (14.07.88)															
(21) International Application Number: PCT/US87/03398 (22) International Filing Date: 21 December 1987 (21.12.87) (31) Priority Application Numbers: 946,415 132,136 (32) Priority Dates: 24 December 1986 (24.12.86) 18 December 1987 (18.12.87) (33) Priority Country: US (71) Applicant: LIPOSOME TECHNOLOGY, INC. [US/ US]; 1050 Hamilton Court, Menlo Park, CA 94025 (US). (72) Inventors: ALLEN, Theresa, M. ; 11223 72nd Avenue, Alberta, T6G 0B4 (CA). GABIZON, Alberto ; 135 Font Boulevard, San Francisco, CA 94132 (US).		(74) Agents: DEHLINGER, Peter, J. et al.; Ciotti & Mu- rashige, Irell & Manella, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US). (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), DK, FR (European patent), GB (Euro- pean patent), IT (European patent), JP, LU (Euro- pean patent), NL (European patent), NO, SE (Euro- pean patent). Published <i>With international search report.</i>															
(54) Title: LIPOSOMES WITH ENHANCED CIRCULATION TIME																	
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>(57) Abstract</p> <p>A composition of liposomes which contain an en- trapped pharmaceutical agent and are characterized by (a) liposome sizes predominantly between about 0.07 and 0.5 microns; (b) at least about 50 mole percent of a membrane-rigidifying lipid, such as sphingomyelin or neutral phospholipids with predominantly saturated acyl chains; and (c) between about 5-20 mole percent of a glycolipid selected from the group consisting of gang- lioside GM₁, saturated phosphatidylinositol, and galac- tocerebroside sulfate ester. The liposomes in which a drug is entrapped are administered intravenously in a suspension as therapeutic drug treatment, and the lipo- somes have enhanced circulation time in the blood- stream.</p> </div> <div style="width: 50%;"> <table border="1"> <caption>Data points estimated from the graph</caption> <thead> <tr> <th>Hours post-injection</th> <th>Blood/MPS ratio (Open Circles)</th> <th>Blood/MPS ratio (Solid Circles)</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>9.5</td> <td>3.0</td> </tr> <tr> <td>1</td> <td>5.5</td> <td>0.5</td> </tr> <tr> <td>6</td> <td>4.0</td> <td>0.1</td> </tr> <tr> <td>24</td> <td>1.5</td> <td>0.0</td> </tr> </tbody> </table> </div> </div>			Hours post-injection	Blood/MPS ratio (Open Circles)	Blood/MPS ratio (Solid Circles)	0	9.5	3.0	1	5.5	0.5	6	4.0	0.1	24	1.5	0.0
Hours post-injection	Blood/MPS ratio (Open Circles)	Blood/MPS ratio (Solid Circles)															
0	9.5	3.0															
1	5.5	0.5															
6	4.0	0.1															
24	1.5	0.0															

*(Referred to in PCT Gazette No. 19/1988, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				